Can MRI predict finasteride failure? new study seeks answers

NCT ID NCT04288427

Recruiting now Knowledge-focused Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand why some men with an enlarged prostate (BPH) do not respond to the common drug finasteride. Researchers will follow 120 men starting finasteride, tracking their symptoms and using MRI scans and genetic tests over three years. The goal is to find ways to predict resistance early, so non-responders can try other treatments sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Finasteride
What this could lead to: If successful, this could help doctors identify non-responders to finasteride before treatment, saving time and offering alternative therapies sooner.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to a new therapy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia Lower Urinary Tract Symptoms prostate disorder urinary system disorder urinary tract obstruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN PROSTATIC HYPERPLASIA LOWER URINARY TRACT SYMPTOMS PROSTATE DISEASE PROSTATE HYPERPLASIA PROSTATE HYPERTROPHY PROSTATE PAIN URINARY OBSTRUCTION URINARY TRACT DISEASE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.